Stephens Downgrades Exact Sciences (EXAS) to Equal Weight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
Go back to Stephens Downgrades Exact Sciences (EXAS) to Equal Weight
February 25, 2016 9:29 AM EST
Jefferies maintained a Buy rating on Exact Sciences (NASDAQ: EXAS), and cut the price target to $13.00 (from $15.00), following the company's 4Q. . In light of the 4Q test volume shortfall, EXAS' initial outlook for flattish trends in 1Q16 was disappointing. EXAS reaffirmed its '16 revenue... More
February 25, 2016 6:56 AM EST
Roth Capital downgraded Exact Sciences (NASDAQ: EXAS) from Buy to Neutral.
For an analyst ratings summary and ratings history on Exact Sciences click here. For more ratings news on Exact Sciences click here.
Shares of Exact Sciences closed at $5.87 yesterday.
...
More
February 24, 2016 1:37 PM EST
Craig-Hallum downgraded Exact Sciences (NASDAQ: EXAS) from Buy to Hold.
For an analyst ratings summary and ratings history on Exact Sciences click here. For more ratings news on Exact Sciences click here.
Shares of Exact Sciences closed at $6.41 yesterday.
...
More
February 24, 2016 7:31 AM EST
Exact Sciences (NASDAQ: EXAS) reported Q4 EPS of ($0.41), $0.06 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $14.4 million versus the consensus estimate of $14.82 million.
2016 Outlook
The company continues to anticipate completing more than 240,000 Cologuard tests during 2016, generating between... More
